2025
Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia
Luskin M, Murakami M, Keating J, Flamand Y, Winer E, Garcia J, Stahl M, Stone R, Wadleigh M, Jaeckle S, Hagopian E, Weinstock D, Liegel J, McMasters M, Wang E, Stock W, DeAngelo D. Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia. Blood 2025, 145: 577-589. PMID: 39374521, DOI: 10.1182/blood.2024025800.Peer-Reviewed Original ResearchConceptsAcute leukemiaPhiladelphia chromosome-positive acute leukemiaRecommended phase 2 dosePh+ acute lymphoblastic leukemiaHematopoietic stem cell transplantationDe novo ALLHematologic remission rateLymphoid blast crisisMaximum tolerated doseStem cell transplantationPhase 1 studyChronic myeloid leukemiaMulticolor flow cytometryAcute lymphoblastic leukemiaVaso-occlusive eventsCytogenetic remissionBlast crisisSymptomatic pancreatitisTolerated doseRemission ratePh+ ALLCell transplantationMedian ageEnzyme elevationLymphoblastic leukemia
2023
Mini-Hyper-CVD Plus Venetoclax for Treatment of Older Adults with Newly Diagnosed Ph-Negative B-ALL or T-ALL
Luskin M, Shimony S, Keating J, Stock W, Hock H, Garcia J, Stahl M, Galinksy I, Leonard R, Weiner H, Flamand Y, Neuberg D, Stone R, Letai A, Winer E, Konopleva M, Jain N, DeAngelo D. Mini-Hyper-CVD Plus Venetoclax for Treatment of Older Adults with Newly Diagnosed Ph-Negative B-ALL or T-ALL. Blood 2023, 142: 2875. DOI: 10.1182/blood-2023-174269.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationAcute lymphoblastic leukemiaMeasurable residual diseaseMulticolor flow cytometryAllogeneic hematopoietic stem cell transplantationCentral nervous systemComplete remissionB-ALLT-ALLOlder ptsPhiladelphia chromosome (Ph)-negative acute lymphoblastic leukemiaFollow-upDiffuse large B-cell lymphomaComplication of cardiac surgeryMRD negativityLarge B-cell lymphomaRefractory acute lymphoblastic leukemiaCentral nervous system leukemiaRelapsed ALLDiagnosed ALLChemo-resistant diseaseHigh-risk geneticsMini-hyper-CVDBCL2 inhibitor venetoclaxMedian follow-up
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply